Resource Type

Journal Article 3

Year

2021 1

2019 1

2015 1

Keywords

relapse 3

DNMT3A 1

acute leukemia 1

acute myeloid leukemia 1

chemotherapy 1

conditioning 1

donor selection 1

graft-versus-host disease 1

haploidentical hematopoietic stem cell transplantation 1

infection 1

modified donor lymphocyte infusion 1

preleukemic stem cell 1

second hematopoietic stem cell transplantation 1

open ︾

Search scope:

排序： Display mode:

hematopoietic stem cells with the preleukemic stem cell property, a requisite of leukemia initiation and relapse

Yuting Tan,Han Liu,Saijuan Chen

Frontiers of Medicine 2015, Volume 9, Issue 4,   Pages 412-420 doi: 10.1007/s11684-015-0423-x

Abstract: newly reported genes that are recurrently mutated in AML have been found to govern the initiation and relapsefull-blown leukemia, the function of this driver mutation appear to persist from AML initiation up to relapsemutations, such as DNMT3A mutations, in AML is a promising strategy for treatment and reduction of relapse

Keywords： preleukemic stem cell     acute myeloid leukemia     relapse     DNMT3A    

HTML PDF Collect

Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation

Meng Lv, Yingjun Chang, Xiaojun Huang

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 45-56 doi: 10.1007/s11684-017-0595-7

Abstract: donor selection based on non-HLA systems, risk-directed strategies for graft-versus-host disease and relapse

Keywords： haploidentical hematopoietic stem cell transplantation     conditioning     graft-versus-host disease     relapse    

HTML PDF Collect

Second unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed acute leukemia post-chemotherapy plus modified donor lymphocyte infusion

Frontiers of Medicine 2021, Volume 15, Issue 5,   Pages 728-739 doi: 10.1007/s11684-021-0833-x

Abstract: Relapse is the main problem after allogeneic hematopoietic stem cell transplantation (allo-HSCT).The outcome of a second allo-HSCT (HSCT2) for relapse post-HSCT has shown promising results in some previousThe cumulative incidences of relapse were 50.0%±9.8% and 53.5%±9.9% at 1 and 2 years post-HSCT2, respectivelyto HSCT1 and percentage of blasts before HSCT2 were independent risk factors for OS post-HSCT2, and relapsewithin 6 months post-HSCT1 was an independent risk factor for DFS and relapse post-HSCT2.

Keywords： second hematopoietic stem cell transplantation     acute leukemia     relapse     chemotherapy     modified donor    

HTML PDF Collect

Title Author Date Type Operation

hematopoietic stem cells with the preleukemic stem cell property, a requisite of leukemia initiation and relapse

Yuting Tan,Han Liu,Saijuan Chen

Journal Article

Everyone has a donor: contribution of the Chinese experience to global practice of haploidentical hematopoietic stem cell transplantation

Meng Lv, Yingjun Chang, Xiaojun Huang

Journal Article

Second unmanipulated allogeneic transplantation could be used as a salvage option for patients with relapsed acute leukemia post-chemotherapy plus modified donor lymphocyte infusion

Journal Article